{"transactions":[{"id":722799,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T20:05:02.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date."}],"balance_after":155000,"derivative":{"exercise_price":1.91,"expiration_date":"2036-06-26","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001193125-26-290470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526290470/ownership.xml","form_type":"4"}},{"id":730653,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-22T20:15:09.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":51000,"derivative":{"exercise_price":3.62,"expiration_date":"2036-06-17","underlying":"Class A Ordinary Shares","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0001612551-26-000002","document":"form4-06222026_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000161255126000002/form4-06222026_040605.xml","form_type":"4"}},{"id":744216,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-10T01:21:02.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date."}],"balance_after":16667,"derivative":{"exercise_price":21.23,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0001628280-26-042041","document":"wk-form4_1781054459.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000162828026042041/wk-form4_1781054459.xml","form_type":"4"}},{"id":744215,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T01:21:02.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":5778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date."}],"balance_after":9799,"source":{"system":"sec-edgar","filing":"0001628280-26-042041","document":"wk-form4_1781054459.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000162828026042041/wk-form4_1781054459.xml","form_type":"4"}},{"id":885059,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T01:48:55.000Z","date":"2026-02-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19089,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As previously reported on a Form 4 filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the \"Closing Date\"), with 19,089 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 19,089 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"As previously reported on a Form 4 filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the \"Closing Date\"), with 19,089 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 19,089 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture."}],"balance_after":38176,"source":{"system":"sec-edgar","filing":"0001193125-26-068063","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526068063/ownership.xml","form_type":"4"}},{"id":977302,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-09T01:02:58.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":6177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date."}],"balance_after":6177,"derivative":{"exercise_price":31.16,"expiration_date":"2035-12-04","underlying":"Common Stock","underlying_shares":6177},"source":{"system":"sec-edgar","filing":"0001628280-25-055927","document":"wk-form4_1765242175.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000162828025055927/wk-form4_1765242175.xml","form_type":"4"}},{"id":977301,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-09T01:02:58.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":16502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"1/3  each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of December 4, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3  each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of December 4, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date."}],"balance_after":16502,"derivative":{"exercise_price":31.16,"expiration_date":"2035-12-04","underlying":"Common Stock","underlying_shares":16502},"source":{"system":"sec-edgar","filing":"0001628280-25-055927","document":"wk-form4_1765242175.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000162828025055927/wk-form4_1765242175.xml","form_type":"4"}},{"id":977300,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T01:02:58.000Z","date":"2025-12-04","kind":"grant","planned":false,"acquired":true,"shares":2021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date."}],"balance_after":4021,"source":{"system":"sec-edgar","filing":"0001628280-25-055927","document":"wk-form4_1765242175.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000162828025055927/wk-form4_1765242175.xml","form_type":"4"}},{"id":1053664,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-28T23:48:20.000Z","date":"2025-02-21","kind":"grant","planned":false,"acquired":true,"shares":57265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issued to the Reporting Person as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. (\"CorHepta\") on February 21, 2025 (the \"Closing Date\") by the Issuer, pursuant to the Agreement and Plan of Merger and Reorganization by and among the Issuer, Project IKT Merger Sub, Inc., CorHepta, and Preston S. Klassen, solely in his capacity as sellers' representative. Of these, 9,544 shares vested on the Closing Date, 28,632 shares shall vest on the first anniversary of the Closing Date. 25% of the remaining 19,089 shares will vest upon achievement of a certain milestone and 75% will vest on the first anniversary of the Closing Date, subject to the Reporting Person's continued service through such date; provided that, if the milestone is not achieved by the first anniversary of the Closing Date, all 19,089 shares shall be forfeited."}],"balance_after":57265,"source":{"system":"sec-edgar","filing":"0001193125-25-191463","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525191463/ownership.xml","form_type":"4"}},{"id":1095288,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T23:43:17.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":108176,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date."}],"balance_after":108176,"derivative":{"exercise_price":1.95,"expiration_date":"2032-06-30","underlying":"Common Stock","underlying_shares":108176},"source":{"system":"sec-edgar","filing":"0000950170-25-093432","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025093432/ownership.xml","form_type":"4"}},{"id":1104604,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-20T11:00:11.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":720,"derivative":{"exercise_price":3.22,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":720},"source":{"system":"sec-edgar","filing":"0000950170-25-088166","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000095017025088166/ownership.xml","form_type":"4"}},{"id":1137420,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-05-22T21:37:10.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in twelve substantially equal monthly installments over a one-year period measured from May 21, 2025; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":51000,"derivative":{"exercise_price":1.03,"expiration_date":"2035-05-21","underlying":"Class A Ordinary Shares","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0001415889-25-014223","document":"form4-05222025_090505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000141588925014223/form4-05222025_090505.xml","form_type":"4"}},{"id":1260148,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T01:11:57.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":116585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026."}],"balance_after":116585,"derivative":{"exercise_price":2.35,"expiration_date":"2035-02-14","underlying":"Common Stock","underlying_shares":116585},"source":{"system":"sec-edgar","filing":"0000950170-25-023586","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025023586/ownership.xml","form_type":"4"}},{"id":1260147,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T01:11:57.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":56600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vested and became exercisable on February 14, 2025."}],"balance_after":56600,"derivative":{"exercise_price":2.35,"expiration_date":"2035-02-14","underlying":"Common Stock","underlying_shares":56600},"source":{"system":"sec-edgar","filing":"0000950170-25-023586","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025023586/ownership.xml","form_type":"4"}},{"id":1335861,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-12-11T21:45:12.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":117000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in twelve substantially equal monthly installments over a one-year period measured from October 23, 2024; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":117000,"derivative":{"exercise_price":2.76,"expiration_date":"2034-12-09","underlying":"Class A Ordinary Shares","underlying_shares":117000},"source":{"system":"sec-edgar","filing":"0001415889-24-028974","document":"form4-12112024_041207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000141588924028974/form4-12112024_041207.xml","form_type":"4"}},{"id":1382387,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-23T23:43:35.000Z","date":"2024-10-21","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares vest 50% on each of the first two anniversaries of October 21, 2024."}],"balance_after":60000,"derivative":{"exercise_price":2.22,"expiration_date":"2034-10-21","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-116780","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017024116780/ownership.xml","form_type":"4"}},{"id":1382386,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-23T23:43:35.000Z","date":"2024-10-21","kind":"purchase","planned":false,"acquired":true,"shares":365000,"price":1.37,"value":500050.0,"ownership":{"direct":false,"nature":"By Amit Munshi Revocable Trust"},"balance_after":365000,"source":{"system":"sec-edgar","filing":"0000950170-24-116780","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017024116780/ownership.xml","form_type":"4"}},{"id":1412820,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A ordinary shares","published_at":"2024-09-06T21:32:12.000Z","date":"2024-04-22","kind":"grant","planned":false,"acquired":true,"shares":159744,"price":3.13,"value":499998.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 24, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'A' instead of transaction code 'P'."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were acquired in a private placement transaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and the Reporting Person at a purchase price of $3.13 per share."}],"balance_after":777384,"source":{"system":"sec-edgar","filing":"0001415889-24-023028","document":"form4a-09062024_090909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000141588924023028/form4a-09062024_090909.xml","form_type":"4/A","original_submission_date":"2024-04-24"}},{"id":1471698,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T20:00:06.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 20, 2024, the date of the Issuer's 2024 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":0.49,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-24-076188","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000095017024076188/ownership.xml","form_type":"4"}},{"id":1536259,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A ordinary shares","published_at":"2024-04-24T22:52:14.000Z","date":"2024-04-22","kind":"purchase","planned":false,"acquired":true,"shares":159744,"price":3.13,"value":499998.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired in a private placement\ntransaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and the Reporting Person at a purchase price of $3.13 per share."}],"balance_after":777384,"source":{"system":"sec-edgar","filing":"0001415889-24-011480","document":"form4-04242024_100408.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000141588924011480/form4-04242024_100408.xml","form_type":"4"}},{"id":1853832,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T20:00:16.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2023, the date of the Issuer's 2023 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":2.12,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-23-037286","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000120919123037286/doc4.xml","form_type":"4"}},{"id":1867376,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-06-05T23:15:15.000Z","date":"2023-06-05","kind":"purchase","planned":false,"acquired":true,"shares":117647,"price":4.25,"value":499999.75,"ownership":{"direct":true},"balance_after":617640,"source":{"system":"sec-edgar","filing":"0001104659-23-068206","document":"tm2310288-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923068206/tm2310288-1_4seq1.xml","form_type":"4"}},{"id":1870244,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Share Option (Right to Buy)","published_at":"2023-06-03T00:45:24.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":1130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person was granted an option to purchase 1,130,000 Class A Ordinary Shares of the Issuer (the \"Option\") on June 1, 2023 (the \"Grant Date\"). The Option is vested and nonforfeitable as of the Grant Date. 25% of the Option shall become exercisable on June 1, 2024 and a further 2.083% of it shall become exercisable at the end of each month thereafter."}],"balance_after":1130000,"derivative":{"exercise_price":6.25,"expiration_date":"2033-06-01","underlying":"Class A Ordinary Shares","underlying_shares":1130000},"source":{"system":"sec-edgar","filing":"0001104659-23-067722","document":"tm2317618-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923067722/tm2317618-1_4seq1.xml","form_type":"4"}},{"id":2231085,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-15T20:00:31.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":1.98,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-22-036936","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000120919122036936/doc4.xml","form_type":"4"}},{"id":2338145,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Performance Restricted Stock Unit","published_at":"2022-03-11T16:11:40.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":42000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an \"Issuer PRSU\") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an \"Issuer PRSU\") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an \"Issuer PRSU\") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an \"Issuer PRSU\") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001628280-22-005889","document":"wf-form4_164703301512029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005889/wf-form4_164703301512029.xml","form_type":"4"}},{"id":2338144,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-11T16:11:40.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":168000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":80.08,"underlying":"Common Stock","underlying_shares":168000},"source":{"system":"sec-edgar","filing":"0001628280-22-005889","document":"wf-form4_164703301512029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005889/wf-form4_164703301512029.xml","form_type":"4"}},{"id":2338143,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-11T16:11:40.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":270000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":44.6,"underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001628280-22-005889","document":"wf-form4_164703301512029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005889/wf-form4_164703301512029.xml","form_type":"4"}},{"id":2338142,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-11T16:11:40.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":285000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":40.94,"underlying":"Common Stock","underlying_shares":285000},"source":{"system":"sec-edgar","filing":"0001628280-22-005889","document":"wf-form4_164703301512029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005889/wf-form4_164703301512029.xml","form_type":"4"}},{"id":2338141,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-11T16:11:40.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":310000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":35.6,"underlying":"Common Stock","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0001628280-22-005889","document":"wf-form4_164703301512029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005889/wf-form4_164703301512029.xml","form_type":"4"}},{"id":2338140,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-11T16:11:40.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":56861,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":14.6,"underlying":"Common Stock","underlying_shares":56861},"source":{"system":"sec-edgar","filing":"0001628280-22-005889","document":"wf-form4_164703301512029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005889/wf-form4_164703301512029.xml","form_type":"4"}},{"id":2338139,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-11T16:11:40.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":138139,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":15.5,"underlying":"Common Stock","underlying_shares":138139},"source":{"system":"sec-edgar","filing":"0001628280-22-005889","document":"wf-form4_164703301512029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005889/wf-form4_164703301512029.xml","form_type":"4"}},{"id":2338138,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-11T16:11:40.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":85847,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a \"2022 Issuer RSU\") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a \"2022 Issuer RSU\") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-22-005889","document":"wf-form4_164703301512029.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005889/wf-form4_164703301512029.xml","form_type":"4"}},{"id":2338137,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-11T16:11:40.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":28800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an \"Issuer RSU\"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an \"Issuer RSU\"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes."}],"balance_after":85847,"source":{"system":"sec-edgar","filing":"0001628280-22-005889","document":"wf-form4_164703301512029.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005889/wf-form4_164703301512029.xml","form_type":"4"}},{"id":2338136,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-11T16:11:40.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":250,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."}],"balance_after":114647,"source":{"system":"sec-edgar","filing":"0001628280-22-005889","document":"wf-form4_164703301512029.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005889/wf-form4_164703301512029.xml","form_type":"4"}},{"id":2338135,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-11T16:11:40.000Z","date":"2022-03-08","kind":"gift","acquired":false,"shares":10500,"price":98.51,"value":1034355.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person gifted the shares to a 501(c)(3) public charity."}],"balance_after":114897,"source":{"system":"sec-edgar","filing":"0001628280-22-005889","document":"wf-form4_164703301512029.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005889/wf-form4_164703301512029.xml","form_type":"4"}},{"id":2445259,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-01-05T17:01:50.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":85847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on February 15, 2023, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of May, August, November, and February. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":125397,"source":{"system":"sec-edgar","filing":"0001628280-22-000341","document":"wf-form4_164142005362510.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022000341/wf-form4_164142005362510.xml","form_type":"4"}},{"id":2600949,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-17T08:30:31.000Z","date":"2021-08-16","kind":"purchase","acquired":true,"shares":1000,"price":48.19,"value":48190.0,"ownership":{"direct":true},"balance_after":39550,"source":{"system":"sec-edgar","filing":"0001628280-21-017167","document":"wf-form4_162920341025660.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021017167/wf-form4_162920341025660.xml","form_type":"4"}},{"id":2604205,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-13T08:10:13.000Z","date":"2021-08-12","kind":"purchase","acquired":true,"shares":1000,"price":50.41,"value":50410.0,"ownership":{"direct":true},"balance_after":38550,"source":{"system":"sec-edgar","filing":"0001628280-21-016916","document":"wf-form4_162885659907660.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021016916/wf-form4_162885659907660.xml","form_type":"4"}},{"id":2607418,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-11T08:04:59.000Z","date":"2021-08-10","kind":"purchase","acquired":true,"shares":1000,"price":52.915,"value":52915.0,"ownership":{"direct":true},"balance_after":37550,"source":{"system":"sec-edgar","filing":"0001628280-21-016504","document":"wf-form4_162868348096069.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021016504/wf-form4_162868348096069.xml","form_type":"4"}},{"id":2815596,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Performance Restricted Stock Unit","published_at":"2021-03-03T21:32:03.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Employee Performance Restricted Stock Unit (\"PRSU\") represents a contingent right to receive shares of Arena's common stock, which shares shall vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from March 1, 2021, through February 29, 2024 (the \"Performance Period\") and satisfaction of a continuing service requirement. The reporting person was granted a \"target\" number of PRSUs equal to 50% of the number reported in Column 5. This Form 4 reports the \"maximum\" number of PRSUs, which equals 200% of \"target\" PRSUs, in order to reflect the maximum number of common shares issuable to the reporting person pursuant to the PRSUs."},{"field":"shares","element":"transactionShares","label":"F4","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs."}],"balance_after":42000,"derivative":{"expiration_date":"2024-02-29","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001209191-21-017582","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121017582/doc4.xml","form_type":"4"}},{"id":2815595,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-03-03T21:32:03.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":168000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest over four years, with 25% of the shares subject to the option vesting on March 1, 2022, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":168000,"derivative":{"exercise_price":80.08,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":168000},"source":{"system":"sec-edgar","filing":"0001209191-21-017582","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121017582/doc4.xml","form_type":"4"}},{"id":2815594,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-03T21:32:03.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":28800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on May 15, 2022, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of August, November, February, and May. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":36550,"source":{"system":"sec-edgar","filing":"0001209191-21-017582","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121017582/doc4.xml","form_type":"4"}},{"id":2888267,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-02T02:45:59.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":15000,"derivative":{"exercise_price":1.47,"expiration_date":"2031-01-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-21-002327","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315221002327/ownership.xml","form_type":"4"}},{"id":2903069,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-20T21:05:54.000Z","date":"2021-01-19","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":138139,"derivative":{"exercise_price":15.5,"expiration_date":"2023-05-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-004584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121004584/doc4.xml","form_type":"4"}},{"id":2903068,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-20T21:05:54.000Z","date":"2021-01-15","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":188139,"derivative":{"exercise_price":15.5,"expiration_date":"2023-05-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-004584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121004584/doc4.xml","form_type":"4"}},{"id":2903067,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-20T21:05:54.000Z","date":"2021-01-19","kind":"sale","acquired":false,"shares":50000,"price":80.1352,"value":4006760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.91, inclusive."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001209191-21-004584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121004584/doc4.xml","form_type":"4"}},{"id":2903066,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-20T21:05:54.000Z","date":"2021-01-19","kind":"exercise","acquired":true,"shares":50000,"price":15.5,"value":775000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":57750,"source":{"system":"sec-edgar","filing":"0001209191-21-004584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121004584/doc4.xml","form_type":"4"}},{"id":2903065,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-20T21:05:54.000Z","date":"2021-01-15","kind":"sale","acquired":false,"shares":2900,"price":81.055,"value":235059.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001209191-21-004584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121004584/doc4.xml","form_type":"4"}},{"id":2903064,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-20T21:05:54.000Z","date":"2021-01-15","kind":"sale","acquired":false,"shares":47100,"price":80.1893,"value":3776916.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.92, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4."}],"balance_after":10650,"source":{"system":"sec-edgar","filing":"0001209191-21-004584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121004584/doc4.xml","form_type":"4"}},{"id":2903063,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-20T21:05:54.000Z","date":"2021-01-15","kind":"exercise","acquired":true,"shares":50000,"price":15.5,"value":775000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":57750,"source":{"system":"sec-edgar","filing":"0001209191-21-004584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121004584/doc4.xml","form_type":"4"}},{"id":2907527,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-14T20:43:28.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":5396,"price":75.6407,"value":408157.2172,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.36 to $76.14, inclusive."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001209191-21-003703","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121003703/doc4.xml","form_type":"4"}},{"id":2907526,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-14T20:43:28.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":7481,"price":75.0705,"value":561602.4105,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.36 to $75.35, inclusive."}],"balance_after":13146,"source":{"system":"sec-edgar","filing":"0001209191-21-003703","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121003703/doc4.xml","form_type":"4"}},{"id":2907525,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-14T20:43:28.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":2000,"price":73.9048,"value":147809.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.34 to $74.18, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, and 4 to this Form 4."}],"balance_after":20627,"source":{"system":"sec-edgar","filing":"0001209191-21-003703","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121003703/doc4.xml","form_type":"4"}},{"id":2911198,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Restricted Stock Unit","published_at":"2021-01-11T21:17:01.000Z","date":"2021-01-07","kind":"exercise","acquired":false,"shares":23400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount), and another 11,700 of the shares subject to the PRSUs (50% of the target amount) vested in Nov. 2020. The final 23,400 shares issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) vested and released on January 7, 2021, as reported herein."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount), and another 11,700 of the shares subject to the PRSUs (50% of the target amount) vested in Nov. 2020. The final 23,400 shares issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) vested and released on January 7, 2021, as reported herein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount), and another 11,700 of the shares subject to the PRSUs (50% of the target amount) vested in Nov. 2020. The final 23,400 shares issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) vested and released on January 7, 2021, as reported herein."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The amount reported in Column 7 of Table II represents the common shares that vested on January 7, 2021. The PRSUs have now fully vested and no common shares remain issuable thereunder."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount), and another 11,700 of the shares subject to the PRSUs (50% of the target amount) vested in Nov. 2020. The final 23,400 shares issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) vested and released on January 7, 2021, as reported herein."}],"balance_after":0,"derivative":{"expiration_date":"2022-01-03","underlying":"Common Stock","underlying_shares":23400},"source":{"system":"sec-edgar","filing":"0001209191-21-003165","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121003165/doc4.xml","form_type":"4"}},{"id":2911197,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-11T21:17:01.000Z","date":"2021-01-07","kind":"tax_withholding","acquired":false,"shares":8523,"price":77.59,"value":661299.57,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs."}],"balance_after":22627,"source":{"system":"sec-edgar","filing":"0001209191-21-003165","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121003165/doc4.xml","form_type":"4"}},{"id":2911196,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-11T21:17:01.000Z","date":"2021-01-07","kind":"exercise","acquired":true,"shares":23400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount), and another 11,700 of the shares subject to the PRSUs (50% of the target amount) vested in Nov. 2020. The final 23,400 shares issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) vested and released on January 7, 2021, as reported herein."}],"balance_after":31150,"source":{"system":"sec-edgar","filing":"0001209191-21-003165","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121003165/doc4.xml","form_type":"4"}},{"id":2952237,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-12-09T16:02:20.000Z","date":"2020-12-08","kind":"sale","acquired":false,"shares":6517,"price":70.0013,"value":456198.4721,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.02, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001209191-20-062473","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120062473/doc4.xml","form_type":"4"}},{"id":2964605,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Restricted Stock Unit","published_at":"2020-11-30T16:00:18.000Z","date":"2020-11-25","kind":"exercise","acquired":false,"shares":11700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 11,700 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 23,400 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 11,700 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 23,400 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 11,700 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 23,400 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The amount reported in Column 7 of Table II represents the common shares that vested on November 25, 2020. The PRSUs' final Closing Price target has been met and the Reporting Person has a contingent right to receive 23,400 additional common shares if the subsequent continuing service requirement is met."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 11,700 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 23,400 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement."}],"balance_after":23400,"derivative":{"expiration_date":"2022-01-03","underlying":"Common Stock","underlying_shares":11700},"source":{"system":"sec-edgar","filing":"0001209191-20-060717","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120060717/doc4.xml","form_type":"4"}},{"id":2964604,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-30T16:00:18.000Z","date":"2020-11-25","kind":"tax_withholding","acquired":false,"shares":5183,"price":65.5,"value":339486.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs."}],"balance_after":14267,"source":{"system":"sec-edgar","filing":"0001209191-20-060717","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120060717/doc4.xml","form_type":"4"}},{"id":2964603,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-30T16:00:18.000Z","date":"2020-11-25","kind":"exercise","acquired":true,"shares":11700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 11,700 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 23,400 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement."}],"balance_after":19450,"source":{"system":"sec-edgar","filing":"0001209191-20-060717","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120060717/doc4.xml","form_type":"4"}},{"id":2992200,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-05T01:00:14.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":1844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4793},"source":{"system":"sec-edgar","filing":"0000899243-20-030413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000089924320030413/doc4.xml","form_type":"4"}},{"id":2992199,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-05T01:00:14.000Z","date":"2020-09-25","kind":"grant","acquired":true,"shares":1844,"price":27.11,"value":49990.84,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date."}],"balance_after":1844,"derivative":{"underlying":"Common Stock","underlying_shares":4793},"source":{"system":"sec-edgar","filing":"0000899243-20-030413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000089924320030413/doc4.xml","form_type":"4"}},{"id":2992198,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-11-05T01:00:14.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":109187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to such option vest and become exercisable on May 19, 2021 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."}],"balance_after":109187,"derivative":{"exercise_price":1.95,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":109187},"source":{"system":"sec-edgar","filing":"0000899243-20-030413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000089924320030413/doc4.xml","form_type":"4"}},{"id":2992197,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-05T01:00:14.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":4793,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date."}],"balance_after":4793,"source":{"system":"sec-edgar","filing":"0000899243-20-030413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612551/000089924320030413/doc4.xml","form_type":"4"}},{"id":3043955,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-08-31T20:41:14.000Z","date":"2020-08-31","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and were exercisable once vested."}],"balance_after":238139,"derivative":{"exercise_price":15.5,"expiration_date":"2023-05-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-20-048864","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120048864/doc4.xml","form_type":"4"}},{"id":3043954,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-08-31T20:41:14.000Z","date":"2020-08-28","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and were exercisable once vested."}],"balance_after":288139,"derivative":{"exercise_price":15.5,"expiration_date":"2023-05-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-20-048864","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120048864/doc4.xml","form_type":"4"}},{"id":3043953,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-08-31T20:41:14.000Z","date":"2020-08-31","kind":"sale","acquired":false,"shares":50000,"price":70.1007,"value":3505035.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001209191-20-048864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120048864/doc4.xml","form_type":"4"}},{"id":3043952,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-08-31T20:41:14.000Z","date":"2020-08-31","kind":"exercise","acquired":true,"shares":50000,"price":15.5,"value":775000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":57750,"source":{"system":"sec-edgar","filing":"0001209191-20-048864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120048864/doc4.xml","form_type":"4"}},{"id":3043951,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-08-31T20:41:14.000Z","date":"2020-08-28","kind":"sale","acquired":false,"shares":50000,"price":70,"value":3500000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001209191-20-048864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120048864/doc4.xml","form_type":"4"}},{"id":3043950,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-08-31T20:41:14.000Z","date":"2020-08-28","kind":"exercise","acquired":true,"shares":50000,"price":15.5,"value":775000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":57750,"source":{"system":"sec-edgar","filing":"0001209191-20-048864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120048864/doc4.xml","form_type":"4"}},{"id":3122468,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-06-04T18:34:52.000Z","date":"2020-06-03","kind":"exercise","acquired":false,"shares":41861,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":338139,"derivative":{"exercise_price":15.5,"expiration_date":"2023-05-11","underlying":"Common Stock","underlying_shares":41861},"source":{"system":"sec-edgar","filing":"0001209191-20-034542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120034542/doc4.xml","form_type":"4"}},{"id":3122467,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-06-04T18:34:52.000Z","date":"2020-06-03","kind":"exercise","acquired":false,"shares":8139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":56861,"derivative":{"exercise_price":14.6,"expiration_date":"2024-02-13","underlying":"Common Stock","underlying_shares":8139},"source":{"system":"sec-edgar","filing":"0001209191-20-034542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120034542/doc4.xml","form_type":"4"}},{"id":3122466,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-06-04T18:34:52.000Z","date":"2020-06-02","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":65000,"derivative":{"exercise_price":14.6,"expiration_date":"2024-02-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-20-034542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120034542/doc4.xml","form_type":"4"}},{"id":3122465,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-04T18:34:52.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":17962,"price":69.2581,"value":1244013.9922,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.97 to $69.68, inclusive."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001209191-20-034542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120034542/doc4.xml","form_type":"4"}},{"id":3122464,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-04T18:34:52.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":20028,"price":68.6146,"value":1374213.2088,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.94 to $68.93, inclusive."}],"balance_after":25712,"source":{"system":"sec-edgar","filing":"0001209191-20-034542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120034542/doc4.xml","form_type":"4"}},{"id":3122463,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-04T18:34:52.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":12010,"price":67.3613,"value":809009.213,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.91 to $67.87, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, and 4 to this Form 4."}],"balance_after":45740,"source":{"system":"sec-edgar","filing":"0001209191-20-034542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120034542/doc4.xml","form_type":"4"}},{"id":3122462,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-04T18:34:52.000Z","date":"2020-06-03","kind":"exercise","acquired":true,"shares":41861,"price":15.5,"value":648845.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":57750,"source":{"system":"sec-edgar","filing":"0001209191-20-034542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120034542/doc4.xml","form_type":"4"}},{"id":3122461,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-04T18:34:52.000Z","date":"2020-06-03","kind":"exercise","acquired":true,"shares":8139,"price":14.6,"value":118829.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":15889,"source":{"system":"sec-edgar","filing":"0001209191-20-034542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120034542/doc4.xml","form_type":"4"}},{"id":3122460,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-04T18:34:52.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":50000,"price":65,"value":3250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001209191-20-034542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120034542/doc4.xml","form_type":"4"}},{"id":3122459,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-04T18:34:52.000Z","date":"2020-06-02","kind":"exercise","acquired":true,"shares":50000,"price":14.6,"value":730000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":57750,"source":{"system":"sec-edgar","filing":"0001209191-20-034542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120034542/doc4.xml","form_type":"4"}},{"id":3137791,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-05-22T19:31:26.000Z","date":"2020-05-22","kind":"exercise","acquired":false,"shares":34800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":115000,"derivative":{"exercise_price":14.6,"expiration_date":"2024-02-13","underlying":"Common Stock","underlying_shares":34800},"source":{"system":"sec-edgar","filing":"0001209191-20-031876","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120031876/doc4.xml","form_type":"4"}},{"id":3137790,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-05-22T19:31:26.000Z","date":"2020-05-21","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":149800,"derivative":{"exercise_price":14.6,"expiration_date":"2024-02-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-20-031876","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120031876/doc4.xml","form_type":"4"}},{"id":3137789,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-22T19:31:26.000Z","date":"2020-05-22","kind":"sale","acquired":false,"shares":6462,"price":59.1174,"value":382016.6388,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.22, inclusive."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001209191-20-031876","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120031876/doc4.xml","form_type":"4"}},{"id":3137788,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-22T19:31:26.000Z","date":"2020-05-22","kind":"sale","acquired":false,"shares":13931,"price":58.6075,"value":816461.0825,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.97, inclusive."}],"balance_after":14212,"source":{"system":"sec-edgar","filing":"0001209191-20-031876","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120031876/doc4.xml","form_type":"4"}},{"id":3137787,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-22T19:31:26.000Z","date":"2020-05-22","kind":"sale","acquired":false,"shares":9017,"price":57.5205,"value":518662.3485,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.07 to $57.97, inclusive."}],"balance_after":28143,"source":{"system":"sec-edgar","filing":"0001209191-20-031876","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120031876/doc4.xml","form_type":"4"}},{"id":3137786,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-22T19:31:26.000Z","date":"2020-05-22","kind":"sale","acquired":false,"shares":5390,"price":56.6731,"value":305468.009,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.19 to $56.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, 4, and 5 to this Form 4."}],"balance_after":37160,"source":{"system":"sec-edgar","filing":"0001209191-20-031876","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120031876/doc4.xml","form_type":"4"}},{"id":3137785,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-22T19:31:26.000Z","date":"2020-05-22","kind":"exercise","acquired":true,"shares":34800,"price":14.6,"value":508080.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":42550,"source":{"system":"sec-edgar","filing":"0001209191-20-031876","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120031876/doc4.xml","form_type":"4"}},{"id":3137784,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-22T19:31:26.000Z","date":"2020-05-21","kind":"sale","acquired":false,"shares":50000,"price":55,"value":2750000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001209191-20-031876","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120031876/doc4.xml","form_type":"4"}},{"id":3137783,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-22T19:31:26.000Z","date":"2020-05-21","kind":"exercise","acquired":true,"shares":50000,"price":14.6,"value":730000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":57750,"source":{"system":"sec-edgar","filing":"0001209191-20-031876","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120031876/doc4.xml","form_type":"4"}},{"id":3182369,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T22:55:12.000Z","date":"2020-04-02","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on May 2, 2020, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":10000,"derivative":{"exercise_price":1.28,"expiration_date":"2030-04-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-20-010246","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574235/000089924320010246/doc4.xml","form_type":"4"}},{"id":3234177,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-03T18:07:55.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over four years, with 25% of the shares subject to the option vesting on March 1, 2021, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":270000,"derivative":{"exercise_price":44.6,"expiration_date":"2027-03-01","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001209191-20-015567","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120015567/doc4.xml","form_type":"4"}},{"id":3271601,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-02-14T19:37:52.000Z","date":"2020-02-13","kind":"exercise","acquired":false,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":199800,"derivative":{"exercise_price":14.6,"expiration_date":"2024-02-13","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001209191-20-009831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120009831/doc4.xml","form_type":"4"}},{"id":3271600,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-02-14T19:37:52.000Z","date":"2020-02-13","kind":"sale","acquired":false,"shares":15200,"price":55,"value":836000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001209191-20-009831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120009831/doc4.xml","form_type":"4"}},{"id":3271599,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-02-14T19:37:52.000Z","date":"2020-02-13","kind":"exercise","acquired":true,"shares":15200,"price":14.6,"value":221920.0,"ownership":{"direct":true},"balance_after":22950,"source":{"system":"sec-edgar","filing":"0001209191-20-009831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120009831/doc4.xml","form_type":"4"}},{"id":3285026,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-02-07T16:31:46.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":7129,"price":50,"value":356450.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":7750,"source":{"system":"sec-edgar","filing":"0001209191-20-007531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120007531/doc4.xml","form_type":"4"}},{"id":3312424,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-13T22:15:20.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 9, 2020, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":15000,"derivative":{"exercise_price":1.54,"expiration_date":"2030-01-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-20-001090","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574235/000089924320001090/doc4.xml","form_type":"4"}},{"id":3393090,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Restricted Stock Unit","published_at":"2019-10-16T20:17:30.000Z","date":"2019-10-14","kind":"exercise","acquired":false,"shares":11700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 11,700 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 35,100 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 11,700 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 35,100 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 11,700 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 35,100 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The amount reported in Column 7 of Table II represents the common shares that vested on October 14, 2019. Under the PRSUs, the Reporting Person has a contingent right to receive up to 35,100 additional common shares if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 11,700 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 35,100 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met."}],"balance_after":35100,"derivative":{"expiration_date":"2022-01-03","underlying":"Common Stock","underlying_shares":11700},"source":{"system":"sec-edgar","filing":"0001209191-19-053332","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119053332/doc4.xml","form_type":"4"}},{"id":3393089,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-16T20:17:30.000Z","date":"2019-10-14","kind":"tax_withholding","acquired":false,"shares":4571,"price":47.32,"value":216299.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs."}],"balance_after":14879,"source":{"system":"sec-edgar","filing":"0001209191-19-053332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119053332/doc4.xml","form_type":"4"}},{"id":3393088,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-16T20:17:30.000Z","date":"2019-10-14","kind":"exercise","acquired":true,"shares":11700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 11,700 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 35,100 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 62 shares acquired on June 30, 2017, pursuant to the 2009 Arena Employee Stock Purchase Plan."}],"balance_after":19450,"source":{"system":"sec-edgar","filing":"0001209191-19-053332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119053332/doc4.xml","form_type":"4"}},{"id":3518028,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":34471,"kind":"person","name":"Munshi Amit","position":1,"cik":"0001612551","reported_name":"Munshi Amit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-20T20:12:25.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":15000,"derivative":{"exercise_price":1.06,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-19-014139","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574235/000089924319014139/doc4.xml","form_type":"4"}}],"next_cursor":"2019-05-20T20:12:25.000000Z,3518028"}